Intrathecal synthesis of anti-mycobacterial antibodies in patients with tuberculous meningitis. An immunoblotting study

C J M Sindic, D Bouquey, M P Van Antwerpen, M C Baelden, C Laterre, C Cocito

Abstract
Cerebrospinal fluid (CSF) and serum samples from eight patients with bacteriologically proven (6) or clinically suspected (2) tuberculous meningitis were tested for the presence of anti-mycobacterial IgG antibodies by an affinity-mediated immunoblot technique. This technique is based on agarose gel isoelectric focusing of paired CSF and serum samples diluted to the same IgG concentration, and transfer of the specific IgG antibodies onto mycobacterial antigen-loaded nitrocellulose sheets. An intrathecal synthesis of anti-mycobacterial oligoclonal IgG antibodies, often superimposed on diffuse polyclonal production was shown in all patients but not in patients with tension headache or other neurological disorders. Similar results were obtained when a purified mycobacterial antigen, A60, was used for coating the nitrocellulose sheets in place of a whole mycobacterial homogenate, indicating that A60 was a major immunogen. The number of anti-mycobacterial oligoclonal IgG bands increased with time, and persisted for years even in clinically cured patients. Some IgG bands had no detectable anti-mycobacterial activity, at least with the antigens preparations used in this study. The demonstration of such anti-mycobacterial IgG bands in he CSF could be a useful adjunct for the diagnosis of tuberculous meningitis, especially in the case of negative cultures.

Despite a decline in the incidence of tuberculosis in western countries, tuberculous meningitis (TM) has not diminished in proportion and remains a serious illness with fatal consequences, if untreated. The rate and extent of recovery are related, in part, to the rapidity with which an appropriate therapy is initiated. However, a fast and specific test for diagnosis is a prerequisite for early initiation of treatment. The demonstration of Mycobacterium tuberculosis by culture of the cerebrospinal fluid (CSF) is a lengthy process, which delays the diagnosis; moreover, cultures may remain sterile even in cases proven at necropsy. Direct demonstration of tubercular antigens in CSF by radioimmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), and latex agglutination has been reported, but the sensitivities and specificities of these techniques have yet to be assessed. In addition, the presence of antimycobacterial antibodies and/or soluble immune complexes could mask such tubercular antigens. TM is indeed characterised by the intrathecal synthesis of oligoclonal IgG which, in one case, were proved to be directed against mycobacterial antigens. The detection of such anti-mycobacterial antibodies in the CSF by RIA or ELISA would be a useful adjunct for early diagnosis of TM. The antigen composition of M tuberculosis is very complex. Some 30 antigens have been detected by a reference system based on cross immunoelectrophoresis. The less mobile polymer in this system is antigen 60 (A60), which is the main thermostable immunogen of both "old tuberculin" and "purified protein derivative" (PPD), known reagents for cutaneous testing in tuberculosis. A60 was purified from the cytoplasmin of M bovis. It is a high molecular weight complex (10^6-10^7 daltons) containing three moieties of free lipids, lipoplyosaccharides and lipoproteins. This antigen is located in the bacterial cytosol during the exponential growth phase, accumulates in the walls of stationary cells, and is later released extracellularly. A60 is a powerful immunogen inducing primary and secondary humoral responses and delayed hypersensitivity reactions when injected into mice. An A60-based ELISA-type immunoassay has been developed for serological analysis of tuberculosis in humans (Baelden et al, unpublished). The use of A60 as a new tuberculin for cutaneous testing has been proposed.

In this study, an immunoblotting method was applied to CSF and paired sera samples of patients with TM. Using this test the intrathecal synthesis of oligoclonal anti-mycobacterial IgG antibodies was followed. In addition, immunoblotting experiments were performed in parallel with whole mycobacterial homogenates and with the purified antigen A60, to explore the importance of this antigen in the case of intrathecal mycobacterial infection.

Patients (table 1)
We studied eight patients (six females, two males; seven white, one oriental; age: 1-53 years), six of them with bacteriologically proven and two with clinically suspected TM. Three patients were also affected by lung
tuberculosis. The youngest (patient 1) was infected by her grandmother and her sister also had lung tuberculosis. All patients had HIV seronegativity. Initial CSF analysis revealed pleocytosis (mostly lymphocytes) in all cases with high protein content in six and glucose levels below 40 mg/dl in 4. The Ziel-Hel-Nelson staining was positive in one case and the cultures were positive for M tuberculosis in six. Patient 1 died after being in a comatose state for six months. In the other cases the standard anti-tuberculous therapy led to a return to normal CSF values in cell number and glucose levels, although an alteration of the blood-brain barrier persisted in patients 4 and 6. Slight or major sequelae persisted in patients 4, 5 and 6; clinical recovery was complete in four patients (2, 3, 7, 8).

**Materials and methods**

**Samples**

Twenty two CSF and serum paired samples were collected at various intervals from TM patients, up to sixty nine months after onset (table 2). After centrifugation, aliquots of 0.5–2 ml were kept frozen at −20°C. The total protein content of CSF was determined by nephelometry and albumin and IgG in both CSF and serum by immunonephelometry.

**Immunoblotting technique**

The technique used to identify anti-mycobacterial antibodies was similar to the immunoblotting procedure first described by Dörries and Ter Meulen,22 with slight modifications.23,24

Agarose gel plates were prepared with 0.36 g Isogel Agarose-EF for electrofocusing and 4·3 g sorbitol containing 2 ml amphetamine (pH range 3·5–9·5).

The nitrocellulose sheet was dipped overnight into either soluble mycobacterial antigens at a concentration of 300 µg/ml proteins (Lowry method) or A60 at the same protein concentration, and washed in Tris buffer saline (TBS, Tris 20 mM, NaCl 500 mM, pH 7·5) containing 0·1% Tween 20 (Technicon Diagnostics) for 60 minutes with three changes.

**Table 1 Clinical and biological data of patients with tuberculous meningitis**

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Protein (mg/dl)</th>
<th>Cells/µl</th>
<th>Glucose (mg/dl)</th>
<th>Microbiological analysis of CSF</th>
<th>Lung tuberculosis</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>10</td>
<td>106 (10)*</td>
<td>0</td>
<td>60 (104)</td>
<td>+</td>
<td>-</td>
<td>Death</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>17</td>
<td>29 (52)</td>
<td>0</td>
<td>20 (176)</td>
<td>-</td>
<td>Complete recovery</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>53</td>
<td>100 (15)</td>
<td>0</td>
<td>44 (89)</td>
<td>-</td>
<td>Complete recovery</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>14</td>
<td>23 (79)</td>
<td>0</td>
<td>67 (98)</td>
<td>-</td>
<td>-</td>
<td>Major sequelae†</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>14</td>
<td>262 (35)</td>
<td>11 (72)</td>
<td>41 (88)</td>
<td>+</td>
<td>-</td>
<td>Major sequelae†</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>13</td>
<td>5000 (39)</td>
<td>421 (74)</td>
<td>27 (74)</td>
<td>+</td>
<td>-</td>
<td>Complete recovery</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>26</td>
<td>220 (96)</td>
<td>281 (76)</td>
<td>-</td>
<td>-</td>
<td>Complete recovery</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>50</td>
<td>281 (96)</td>
<td>-</td>
<td>15 (76)</td>
<td>-</td>
<td>Complete recovery</td>
<td></td>
</tr>
</tbody>
</table>

*Percentage of lymphocytes in total CSF cells.
†Major sequelae included hydrocephalus, bradypsychia, spastic paraparesis, and tardive syringomyelia.

**Table 2 Biological data of CSF and serum samples studied by immunoblotting**

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Samples number</th>
<th>Time*</th>
<th>CSF analysis</th>
<th>Immunoblotting†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1/1</td>
<td>12d</td>
<td>26 (mg/dl)</td>
<td>Serum</td>
</tr>
<tr>
<td>2</td>
<td>1/2</td>
<td>15d</td>
<td>1000 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3/1</td>
<td>26</td>
<td>46 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4/1</td>
<td>41</td>
<td>95 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>5/1</td>
<td>100</td>
<td>66 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>6/1</td>
<td>60d</td>
<td>143 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>7/1</td>
<td>72</td>
<td>35 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>8/1</td>
<td>85</td>
<td>102 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>9/1</td>
<td>108</td>
<td>95 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>10/1</td>
<td>12m</td>
<td>42 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>11/1</td>
<td>22d</td>
<td>136 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>12/1</td>
<td>31</td>
<td>96 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>13/1</td>
<td>69m</td>
<td>158 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>14/1</td>
<td>47d</td>
<td>270 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>15/1</td>
<td>7m</td>
<td>4200 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>16/1</td>
<td>20</td>
<td>2600 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>17/1</td>
<td>34</td>
<td>2050 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>18/1</td>
<td>14d</td>
<td>220 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>19/1</td>
<td>27</td>
<td>170 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>20/1</td>
<td>76</td>
<td>195 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>21/1</td>
<td>6m</td>
<td>83 (mg/dl)</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>22/1</td>
<td>7</td>
<td>44 (mg/dl)</td>
<td></td>
</tr>
</tbody>
</table>

*Time after the appearance of clinical symptoms, expressed in days (d) or months (m).
†Paired samples of CSF and serum were tested at the same IgG concentration.
‡Serum glucose levels varied between 68 and 125 mg/dl.
§Percentage of lymphocytes in total CSF cells.
||
A preparation of unfractionated cytoplasmic antigens was obtained by ultrasonication (type B12 Branson Sonifier) of M tuberculosis strain H 37 Ra (Difco Laboratories, Detroit, United States) suspended in Na phosphate buffer 0·1 M, containing 0·15 M NaCl, pH 7·6 (PBS): the homogenate was centrifuged at 6,000 g for 15 minutes at 4°C, the pellet was discarded and the supernatant stored at −20°C.

The mycobacterial antigen A60 was prepared from the cytoplasm of M bovis BCG by exclusion gel chromatography on columns of Sepharose 6B. A60 was identified by crossed immunoelectrophoresis according to a reference system on 1% agarose gel slab using anti-BCG antiserum in the second dimension. A quantitative determination of A60 was made by spectrophotometric measurements of its polysaccharide and protein moieties.

**Results**

Oligoclonal anti-mycobacterial IgG antibodies restricted to, or more marked in the CSF than in the corresponding serum were detected in samples from the six patients with bacteriologically proven TM (table 2; figs 1, 2), but also from the two patients with clinically suspected TM (fig 3, 4, lanes II A and B). In some cases, the oligoclonal bands were barely detectable on a background of polyclonal antibodies but in most cases, the oligoclonal pattern of these antibodies was very pronounced. As CSF and paired sera were tested at the same IgG concentration after appropriate dilutions, the far deeper staining seen in the CSF is an indication of an intrathecal synthesis of these antibodies. The occurrence of such a local synthesis was graded from 0 to ++ + by visual inspection of the immunoblots (table 2). Uniformly negative results were obtained with samples from...
Figure 3 Immunoblots of anti-mycobacterial specific IgG from unconcentrated CSF and the corresponding serum (SER) diluted to the same IgG concentration after isoelectric focusing in agarose gel and transfer by immunofinity to sheets coated with total mycobacterial antigens. Samples 18, 19 and 20 from patient 7 (table 2) were collected at days 14, 27 and 76 after clinical onset of the disease and the total amounts of IgG applied on the gel were 3.5, 2.9 and 2.3 μg respectively. No reaction was observed at day 14, whereas two oligoclonal bands of specific anti-mycobacterial IgG were present in CSF, but not in the serum, at day 27. A similar oligoclonal pattern of specific antibodies, but with a staining intensity slightly different from one band to another, was present in CSF and in serum at day 76.

patients with tension headache (10), sciatica (10), multiple sclerosis (10), viral meningitis (10) or Borrelia burgdorferi meningoradiculitis (5) (fig 2, lane III).

Most samples under study were collected late in the course of the disease. The earliest samples which were collected 12 and 14 days after the appearance of clinical symptoms (1, patient 1 and 18, patient 7) were negative. However, samples collected at days 15 (2, patient 1), 22 (11, patient 3) and 27 (19, patient 7, fig 3), that is, at days 6, 7 and 14 of admission to hospital, were already clearly positive. When serial samples were available, the staining intensity for specific antibodies generally increased with time and reached a peak one to three months after clinical onset. High levels of CSF anti-mycobacterial antibodies were observed in samples 13 (table 2) and 17 (fig 1) from patients 4 and 6; these samples were taken 69 and 34 months respectively, after onset. At this time these patients were considered cured of the tuberculous infection, but presented severe permanent sequelae (therapy was stopped after 18 months). Although an alteration of the permeability of the blood-CSF barrier to plasma proteins was evident in both cases and was likely due to persistent foci of arachnoiditis, glucose level and cell number in the CSF were normal. Intra-thecal synthesis of anti-mycobacterial antibodies, however, was no longer detectable in sample 10 which was taken from patient 2 (table 2), after 12 months of successful treatment.

Similar immunoblotting patterns were obtained when antigen A60 was used for coating the nitrocellulose sheet (fig 2B) in place of a whole mycobacterial homogenate (fig 2A). Indeed, the same oligoclonal IgG bands were detected at the same isoelectric points with similar intensity of staining.

When the complete IgG pattern was compared with that of anti-mycobacterial antibodies (fig 4), it was noted that some IgG bands were not directed against mycobacterial antigens (fig 4, lane I). In addition, it was possible to detect oligoclonal anti-mycobacterial IgG antibodies from the polyclonal background of IgG in CSF as well as in the corresponding serum. The failure therefore to detect oligoclonal IgG bands did not exclude the presence of oligoclonal anti-mycobacterial antibodies.

Discussion

In normal conditions, CSF IgG originate from blood as demonstrated by studies in humans with radiolabelled IgG. Consequently, the relative amounts of IgG antibodies directed against a given antigen should be identical in both fluids even in the case of an altered blood-CSF barrier. In contrast, when immune reactions occur within the central nervous system, the proportion of locally produced antibodies will be higher in CSF than in serum. In our study since paired CSF and serum samples were tested at the same IgG concentration, the results of the immunoblots of both fluids can be directly compared.

With this technique, we were able to detect a local synthesis of antitymocobacterial antibodies in all of the patients with bacteriologically proven or clinically suspected TM. In the two cases with negative cultures positive immunoblotting tests were a valid and the sole biological confirmation of a clinical diagnosis of TM.

Polyclonal and/or oligoclonal anti-mycobacterial specific IgG were detected in samples collected 15 to 27 days after the clinical onset of meningitis. Since cultures of M tuberculosis from CSF samples may yield visible colonies only after six weeks and may also remain sterile even in cases that have been proved at necropsy, the demonstration of the intrathecal synthesis of anti-mycobacterial antibodies appears to be a useful tool for diagnosis of TM. Our data indicate that the synthesis of these antibodies may persist for several years (see late samples from patients 4 and 6, who were considered cured after a standard 18 months treatment). It should be noted that these two patients
presented severe meningoencephalitis, with major sequelae (paraplegia, dysarthria, intellectual impairment), whereas patient 2 (who has completely recovered), had no detectable intrathecal synthesis of IgG antibodies one year after the clinical onset of the disease. The long-lasting intrathecal synthesis of anti-mycobacterial antibodies might be due to the persistence of possibly unviable M tuberculosis within the central nervous system. Another possibility is that immunoregulatory mechanisms for antibody synthesis fail to suppress proliferation and differentiation of B-cell clones after their activation within the brain. Persistence of intrathecal production of antibodies over long periods of time, as long as eight years, has also been reported in other infectious diseases of the nervous system, such as herpetic encephalitis,26 mumps meningitis27 and varicella-zoster meningoencephalitis.28 In contrast, we have observed the spontaneous disappearance of anti-B burgdorferi oligoclonal IgG in some patients recovering from meningitis.29

The presence of some oligoclonal IgG bands restricted to the CSF but devoid of detectable anti-mycobacterial antibody specificity is possibly due to non-specific polyclonal B-cell activation. The intrathecal production of antibodies to unrelated agents was observed in patients with herpetic encephalitis or mumps meningitis.26 27 28 Another explanation could be that our antigen preparations do not contain sufficient amounts of a minor, but highly immunogenic epitope to obtain a transfer by immunoactivity on the nitrocellulose sheet. The fact that the immunoblotting patterns with A60 were similar to those with whole mycobacterial homogenates suggests that most of the intrathecal synthesised IgG in the case of TM were specifically directed against the former antigen.

It should be noted, however, that the structure of A60 is very complex:17 besides the lipoglanin, lipopeptidoglycan and lipid moieties, A60 preparations also contain protein components. After hydrolysis of the protein moiety, the lipoglycan part of A60 is still reactive with anti-BCG antisera.17 This indicates that both protein and polysaccharide moiety might be responsible for the immunogenicity of the antigen. A recent ELISA study31 showed that IgG antibody responses to both a 14-kilodalton protein and lipooarabinomannan were immunodominant in the CSF of TM patients.

We thank Professor P Evrard, Dr F Zech and Dr E Uribere who reviewed the manuscript. To three of us (1, 6, 7 and 8) this work was supported by grants number 5-4529-79 from the "Fonds de la Recherche Scientifique Médicale", Belgium. DB was a research fellow from the "Ministère de la Communauté Française-Recherche Appliquée.

Intrathecal synthesis of anti-mycobacterial antibodies in patients with tuberculous meningitis. An immunoblotting study.

C J Sindic, D Boucquey, M P Van Antwerpen, M C Baelden, C Laterre and C Cocito

J Neurol Neurosurg Psychiatry 1990 53: 662-666
doi: 10.1136/jnnp.53.8.662

Updated information and services can be found at:
http://jnnp.bmj.com/content/53/8/662

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/